Escitalopram Successfully Reduces Hot Flashes

Article

Menopausal women treated with the selective serotonin reuptake inhibitor escitalopram have fewer, and less severe, hot flashes than women taking a placebo, according to a study published in the Jan. 19 issue of the Journal of the American Medical Association.

TUESDAY, Jan. 18 (HealthDay News) -- Menopausal women treated with the selective serotonin reuptake inhibitor escitalopram have fewer, and less severe, hot flashes than women taking a placebo, according to a study published in the Jan. 19 issue of the Journal of the American Medical Association.

Ellen W. Freeman, Ph.D., from the University of Pennsylvania School of Medicine in Philadelphia, and colleagues enrolled 205 healthy menopausal women in a double-blind, placebo-controlled, eight-week trial to test the efficacy of escitalopram as a nonhormonal treatment for hot flashes. Women were randomized to receive 10 to 20 mg per day of escitalopram or a matching placebo and to record the frequency and severity of hot flashes in daily diaries.

The investigators found that women treated with escitalopram had significantly fewer hot flashes per day, and that they were significantly less severe, compared with women taking a placebo. At the eight-week follow-up, 55 percent of women taking escitalopram had a 50 percent or greater reduction in hot flashes, compared with 36 percent of women in the placebo group. Three weeks after the end of treatment, women in the escitalopram group reported an increase in the number of hot flashes compared with women in the placebo group.

"Our findings suggest that among healthy women, 10 to 20 mg/day of escitalopram provides a nonhormonal, off-label option that is effective and well-tolerated in the management of menopausal hot flashes," the authors write.

Escitalopram and placebo provided by Forest Research Institute. Several of the study authors disclosed financial relationships with the pharmaceutical industry, including Forest Laboratories, Inc.

AbstractFull Text (subscription or payment may be required)

Related Content

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Lisa Bayer, MD, MPH
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Non-hormonal treatments offer relief for genitourinary syndrome of menopause | Image Credit: providers.uthscsa.edu.
Jill Liss, MD, MSCP, FACOG, associate clinical professor, OB/GYN, at the University of Colorado School of Medicine.
Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge | Image Credit: wexnermedical.osu.edu
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Giovanni Traverso, PhD, highlights contraceptive implants through small needle | Image Credit: meche.mit.edu
Related Content
© 2025 MJH Life Sciences

All rights reserved.